Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [¹⁸F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer’s disease (AD). The study is designed to compare images from subjects with probable AD with similarly aged and young healthy volunteers (HV). Two trial sites are currently enrolling subjects: Molecular NeuroImaging, LLC in New Haven, CT, which dosed the first patient in the study; and the Alzheimer's Disease Center at Quincy Medical Center in Quincy, MA.

CardioComm Solutions, Inc. Receives Health Canada Approval to Market the HeartCheck™ ECG Monitor as a Prescription Product

CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of ECG acquisition and management software solutions, has received clearance from Health Canada for the sales and marketing of their Class II medical device for prescription based, hand-held ECG monitoring under the HeartCheck™ brand.

The Health Canada licence (89556) was granted August 27, 2012. The HeartCheck™ ECG Monitor can be connected to any computer to upload recorded ECGs to CardioComm Solutionsʼ C4 medical call service and telemedicine group for review by the company’s physicians who will provide ECG interpretations.

Bacterin Secures $25 Million Financing with OrbiMed

Funding provides significant flexibility to execute growth strategy

Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of unique bone graft material and antimicrobial coatings for medical applications, announced the closing of a $25 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC.  The financing will enable Bacterin to execute its growth strategy through anticipated profitability.

Under the terms of the agreement, Bacterin initially received $20 million and has the ability to draw down an additional $5 million based upon the achievement of mutually agreed upon revenue objectives prior to December 31, 2013. 

Anika Therapeutics Reports Record Second Quarter Revenue and Earnings

Total Revenue Grows 22%; Earnings Increase 53% to $0.26 per Share

Anika Therapeutics, Inc. (ANIK), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter ended June 30, 2012.

Revenue

For the second quarter of 2012, Anika’s total revenue increased 22% to $19.6 million, from $16.1 million in the second quarter last year. This growth was primarily driven by higher shipments of Anika’s ophthalmic products, as well as strong domestic and international sales of the company’s flagship product, Orthovisc^®.